Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.56 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863378 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9APDK1PDK2 | |
| SCHEMBL29701086 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9APDK1PDK2 | |
| SCHEMBL2380922 | 0.88 | PDK1 (0.67) | SMN1; SMN2NPC1RAB9APDK1PDK2 | |
| SCHEMBL6981012 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL953545 | 0.88 | PDK1 (0.70) | SMN1; SMN2NPC1RAB9APDK1PDK2 | |
| SCHEMBL952361 | 0.88 | PDK1 (0.70) | SMN1; SMN2NPC1RAB9APDK1PDK2 | |
| SCHEMBL1939593 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL8117814 | 0.88 | PDK1 (0.67) | SMN1; SMN2NPC1RAB9APDK1PDK2 | |
| SCHEMBL29300886 | 0.88 | PDK1 (0.70) | SMN1; SMN2NPC1RAB9APDK1PDK2 | |
| SCHEMBL6654601 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9APDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| EP-1615909-B1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| CN-1809553-A | Piperazine derivatives and their use in the treatment of neurological and psychiatric disorders | GLAXO GROUP LTD (GB) | 2006-07-26 | — | — | CN | disclosed |
| EP-1615909-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004101546-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | SMN1; SMN2 230/4885NPC1 485/4885RAB9A 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.